تقرير
IgA Nephropathy Secondary to Ipilimumab Use.
| العنوان: | IgA Nephropathy Secondary to Ipilimumab Use. |
|---|---|
| المؤلفون: | Dougherty SC; Department of Internal Medicine, University of Virginia, Charlottesville, Virginia, USA., Desai N; Department of Internal Medicine, University of Virginia, Charlottesville, Virginia, USA., Cathro HP; Department of Pathology, University of Virginia, Charlottesville, Virginia, USA., Renaghan A; Department of Internal Medicine, University of Virginia, Charlottesville, Virginia, USA. |
| المصدر: | Case reports in nephrology and dialysis [Case Rep Nephrol Dial] 2021 Nov 15; Vol. 11 (3), pp. 327-333. Date of Electronic Publication: 2021 Nov 15 (Print Publication: 2021). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Karger AG Country of Publication: Switzerland NLM ID: 101636294 Publication Model: eCollection Cited Medium: Print ISSN: 2296-9705 (Print) NLM ISO Abbreviation: Case Rep Nephrol Dial Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel : Karger AG, [2015]- |
| مستخلص: | Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephrotoxicity has been reported less frequently. In this clinical case report, we describe the evaluation of a 70-year-old female with stage IV NSCLC who presented with nephrotic range proteinuria 4 weeks after receiving her first cycle of ipilimumab. She underwent a renal biopsy and was found to have IgA nephropathy that was presumed to be secondary to ipilimumab use, given recent initiation of therapy and clinical history. Unfortunately, despite prompt initiation of corticosteroids, her acute kidney injury progressed and she required hemodialysis, later transitioning to hospice. To our knowledge, this is one of few reported cases of IgA nephropathy secondary to CPI use. With increasing use of CPIs, this case further emphasizes the need for continued surveillance for irAEs, which can occur at any point in a patient's treatment course. Competing Interests: The authors have no conflicts of interest to declare. (Copyright © 2021 by S. Karger AG, Basel.) |
| References: | J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540) Am J Nephrol. 2017;45(2):160-169. (PMID: 28076863) Neurol Clin Pract. 2021 Dec;11(6):e913-e915. (PMID: 34992980) Medicine (Baltimore). 2020 May 22;99(21):e20464. (PMID: 32481351) N Engl J Med. 2019 Nov 21;381(21):2020-2031. (PMID: 31562796) Kidney Int. 2016 Sep;90(3):638-47. (PMID: 27282937) Oncologist. 2013 Jun;18(6):733-43. (PMID: 23774827) J Immunother Cancer. 2019 Jan 6;7(1):2. (PMID: 30612580) Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605) Intern Med. 2018 May 1;57(9):1259-1263. (PMID: 29279511) Intern Med. 2020 Apr 1;59(7):977-981. (PMID: 31813918) Nephrol Dial Transplant. 2017 Jun 1;32(6):936-942. (PMID: 28025384) N Engl J Med. 2018 Jan 11;378(2):158-168. (PMID: 29320654) Immunotherapy. 2016 May;8(5):583-600. (PMID: 27140411) Clin Case Rep. 2021 Jun 22;9(6):e04227. (PMID: 34188921) |
| فهرسة مساهمة: | Keywords: Acute renal failure; Histopathology; IgA nephropathy; Kidney biopsy; Proteinuria |
| تواريخ الأحداث: | Date Created: 20211224 Latest Revision: 20240404 |
| رمز التحديث: | 20240404 |
| مُعرف محوري في PubMed: | PMC8647129 |
| DOI: | 10.1159/000519169 |
| PMID: | 34950709 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-9705 |
|---|---|
| DOI: | 10.1159/000519169 |